ID

23690

Description

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00515112

Lien

https://clinicaltrials.gov/show/NCT00515112

Mots-clés

  1. 10/07/2017 10/07/2017 -
Téléchargé le

10 juillet 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Prostate Cancer NCT00515112

Eligibility Prostate Cancer NCT00515112

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
prostate cancer
Description

ID.1

Type de données

boolean

Alias
UMLS CUI [1]
C0007112
patient must have received primary definitive local therapy to the prostate (surgery and/or radiotherapy)
Description

ID.2

Type de données

boolean

Alias
UMLS CUI [1,1]
C0194790
UMLS CUI [1,2]
C0948317
patient was surgically or pharmacologically castrated at least 6 months prior to starting the study
Description

ID.3

Type de données

boolean

Alias
UMLS CUI [1]
C1319065
patient must have had a previous trial of anti-androgen therapy
Description

ID.4

Type de données

boolean

Alias
UMLS CUI [1]
C0279492
patient must have a rising psa
Description

ID.5

Type de données

boolean

Alias
UMLS CUI [1]
C0201544
no evidence of distant metastatic disease
Description

ID.6

Type de données

boolean

Alias
UMLS CUI [1]
C0027627
ecog performance status < 2
Description

ID.7

Type de données

boolean

age >18 years
Description

ID.8

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
patients must have normal hepatic function
Description

ID.9

Type de données

boolean

Alias
UMLS CUI [1]
C0232741
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with a history of any previous cytotoxic therapy or radionuclide therapy (such as rhenium, strontium, or samarium)
Description

ID.10

Type de données

boolean

Alias
UMLS CUI [1,1]
C0677881
UMLS CUI [1,2]
C0203608
patients may not be receiving any other investigational agents
Description

ID.11

Type de données

boolean

Alias
UMLS CUI [1]
C0013230
uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Description

ID.12

Type de données

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C1321605
patients receiving renal dialysis
Description

ID.13

Type de données

boolean

Alias
UMLS CUI [1]
C0011946
patients with significant pulmonary disease who have received chronic or pulse steroid therapy within the last 3 months prior to randomization will be excluded
Description

ID.14

Type de données

boolean

Alias
UMLS CUI [1,1]
C0024115
patients who have known hypersensitivity to any of the androgel ingredients, including testosterone that is chemically synthesized from soy
Description

ID.15

Type de données

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0875960

Similar models

Eligibility Prostate Cancer NCT00515112

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
prostate cancer
boolean
C0007112 (UMLS CUI [1])
ID.2
Item
patient must have received primary definitive local therapy to the prostate (surgery and/or radiotherapy)
boolean
C0194790 (UMLS CUI [1,1])
C0948317 (UMLS CUI [1,2])
ID.3
Item
patient was surgically or pharmacologically castrated at least 6 months prior to starting the study
boolean
C1319065 (UMLS CUI [1])
ID.4
Item
patient must have had a previous trial of anti-androgen therapy
boolean
C0279492 (UMLS CUI [1])
ID.5
Item
patient must have a rising psa
boolean
C0201544 (UMLS CUI [1])
ID.6
Item
no evidence of distant metastatic disease
boolean
C0027627 (UMLS CUI [1])
ID.7
Item
ecog performance status < 2
boolean
ID.8
Item
age >18 years
boolean
C0001779 (UMLS CUI [1])
ID.9
Item
patients must have normal hepatic function
boolean
C0232741 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
ID.10
Item
patients with a history of any previous cytotoxic therapy or radionuclide therapy (such as rhenium, strontium, or samarium)
boolean
C0677881 (UMLS CUI [1,1])
C0203608 (UMLS CUI [1,2])
ID.11
Item
patients may not be receiving any other investigational agents
boolean
C0013230 (UMLS CUI [1])
ID.12
Item
uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
boolean
C0012634 (UMLS CUI [1,1])
C1321605 (UMLS CUI [1,2])
ID.13
Item
patients receiving renal dialysis
boolean
C0011946 (UMLS CUI [1])
ID.14
Item
patients with significant pulmonary disease who have received chronic or pulse steroid therapy within the last 3 months prior to randomization will be excluded
boolean
C0024115 (UMLS CUI [1,1])
ID.15
Item
patients who have known hypersensitivity to any of the androgel ingredients, including testosterone that is chemically synthesized from soy
boolean
C0020517 (UMLS CUI [1,1])
C0875960 (UMLS CUI [1,2])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial